



Sheet 1 of 1

FEE BASIS PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 01640/1 US	APPLICATION NO.: 10/808,146
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Richard Durley	
(Use several sheets if necessary)		Filed: 3/24/04	Group: 1614 1624

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
DR	1	Trandism Cell Biology; 7; 353-361; 1997
	2	Mol. Cell Biology; 19; 21-30; 1999
	3	Embo J.; 20; 466-479; 2001
	4	Paul et al; Cell Signal; 9; 403-410; 1997
	5	Lee et al; Nature; 372; 376; 1994
	6	J. Biol. Chem; 274; 6272; 1999
	7	JPET; 293; 281; 2000
	8	Boehm et al; Exp Opin Ther Patents; 10; 25; 2000
	9	Rev. Infect. Disease; 6; 51; 1984
	10	Lymphokien Cytokine Res.; 11; 253-256; 1992
	11	Clin. Exp. Immunol.; 989; 244-250; 1992
	12	Perretti, M et al; Br. J. Pharmacol; 110; 868-874; 1993
↓	13	J. M. Stuart; Collagen Autoimmune Arthritis; Annual Rev. Immunol; 2; 199; 1984

EXAMINER <i>Richard Durley</i>	DATE CONSIDERED 3/20/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	